Who
Sanjay Nayak
Chief Strategy Officer
Company insider
Files Form 4 as: Chief Strategy Officer, Ocular Therapeutix.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $405K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Feb 2024
- Last trade
- 24 Aug 2026
- Last filed
- 26 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 26 Aug 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $20K1,897 at $10.78 | filing |
| 24 Aug 2026filed 26 Aug 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $20K1,897 at $10.78 | filing |
| 26 May 2026filed 28 May 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $15K1,858 at $8.20 | filing |
| 26 May 2026filed 28 May 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $15K1,858 at $8.20 | filing |
| 23 Feb 2026filed 25 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $15K1,759 at $8.28 | filing |
| 23 Feb 2026filed 25 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $15K1,759 at $8.28 | filing |
| 12 Feb 2026filed 17 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $94K10,348 at $9.04 | filing |
| 12 Feb 2026filed 17 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $94K10,348 at $9.04 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —64,900 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,650 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,650 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —64,900 at $0.00 | filing |
| 24 Nov 2025filed 26 Nov 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $23K1,878 at $12.04 | filing |
| 25 Aug 2025filed 27 Aug 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $23K1,885 at $12.04 | filing |
| 23 May 2025filed 27 May 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $13K1,862 at $7.17 | filing |
| 24 Feb 2025filed 26 Feb 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $13K1,895 at $6.84 | filing |
| 11 Feb 2025filed 13 Feb 2025 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —334,000 at $0.00 | filing |
| 11 Feb 2025filed 13 Feb 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —111,000 at $0.00 | filing |
| 25 Nov 2024filed 27 Nov 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $16K1,814 at $9.00 | filing |
| 23 Aug 2024filed 27 Aug 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $17K1,832 at $9.02 | filing |
News
Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Sanjay Nayak; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.